The receptor studied by scientists from Kyoto University belongs to the adrenergic receptor family—α2A, α2B, α2C—but none of the approved drugs has the ability to inhibit α2B with high precision. Existing drugs, such as dexmedetomidine, act on a broad spectrum of α2 receptors. They cause sedation and are not intended for oral administration.
ADRIANA (also known as an adrenergic analgesia inducer) is the first known compound to selectively block α2B-adrenergic receptors. The drug does not cause sedation, movement disorders, or cardiovascular problems, reports New Atlas.
The α2B receptor becomes more active after nerve injury. Scientists were able to inhibit it, significantly reducing neuropathic pain in mice. Moreover, the drug is applicable for more than just this type of pain. Preclinical studies have shown its potential for relieving inflammatory and postoperative pain: the drug provided effective pain relief in mice with spinal nerve injury, paw inflammation, and surgical incisions.
"If successfully commercialized, ADRIANA will offer a new, non-opioid-based pain treatment option. This will significantly contribute to reducing the use of opioids in clinical settings," said Masatoshi Hagiwara, co-author of the study.
Clinical trials have shown the drug to be safe and well-tolerated, as well as effective in treating postoperative pain following lung cancer surgery. Phase II trials are currently underway.
Scientists from Australia have developed the PainWaive game, a home-based therapeutic system that helps people with chronic neuropathic pain learn to control their brainwaves and reduce pain without medication. In a pilot study, three out of four participants experienced significant pain relief after just four weeks, comparable to the effects of opioids.
